Problem to be solved: to provide a controlled release solid oral dosage form, including therapeutic effective amounts of predopidine or its pharmaceutically acceptable salt, and at least one pharmacologically acceptable rate control excipient.The controlled release solid oral dosage form results in an in vivo plasma prepyrazine concentration characteristic with an average Cmax of about 1, 400 ng / ml. The invention also provides methods of treating individuals suffering from neurodegenerative disease or dopamine, including one-day administration of a controlled release solid oral dosage form.Diagram【課題】治療上有効量のプリドピジンまたはその薬学的に許容し得る塩、および少なくとも１種の薬学的に許容し得る速度制御賦形剤を含む、調節放出固形経口剤形の提供。【解決手段】調節放出固形経口剤形は、約１，４００ｎｇ／ｍｌ以下の平均Ｃmaxを有するインビボ血漿プリドピジン濃度特性をもたらす。当該発明はまた、調節放出固形経口剤形の１日１回の投与を含む、神経変性疾患またはドーパミンに関連する疾患を患っている個体を処置する方法も提供する。【選択図】図１
